Diginex Bets on $9.6B Supply Chain Compliance Market, but Investors Are Fixated on the Resulticks Countdown

Forced labor affects roughly 50 million people globally, with 86% of victims toiling in the private sector. That staggering statistic underpins the rationale behind Diginex’s latest product push — an end-to-end supply chain due diligence platform dubbed “Risk-to-Remedy.” Yet for all the social urgency and regulatory tailwinds, shareholders have responded with a brutal selloff that has erased more than a third of the stock’s value in 30 days.

The new offering marries three components Diginex has assembled over the past year. LUMEN handles risk assessment across supply chains; APPRISE enables direct worker engagement; and the expertise from The Remedy Project — a firm Diginex acquired earlier — provides complaint mechanisms and remediation protocols. Together, they allow corporate clients to manage audits, collect evidence of abuses, and document corrective actions. The target is companies that must comply with an ever-tightening web of laws, including Germany’s Supply Chain Due Diligence Act, the EU’s CSDDD, and the UK Modern Slavery Act.

The addressable market is sizable and expanding. Analysts peg the global supply chain due diligence market at $3.8 billion in 2025 and expect it to nearly triple to $9.6 billion by 2034. Diginex’s platform positions it squarely in that growth trajectory. But the company’s valuation has been moving in the opposite direction.

Should investors sell immediately? Or is it worth buying Diginex?

Diginex shares closed Friday at $1.00, down 3.85% on the day and 36% over the past month. The relative strength index sits at 29.6, deep in oversold territory. The annualized volatility of more than 155% underscores just how speculative the stock has become since its Nasdaq listing in January 2025. In that time, the company has completed acquisitions worth over $100 million, yet the market remains unconvinced.

A much larger deal is the source of the current anxiety. Diginex has agreed to acquire Resulticks Global Companies for $1.5 billion — an all-stock transaction that would inject roughly $150 million in annual revenue and EBITDA between $46 million and $50 million into the group. The acquisition would also push Diginex beyond sustainability data into real-time decision-making and customer loyalty analytics. But the deal has hit snags. The closing deadline was recently extended to June 12, 2026, as several conditions remain unsatisfied.

That timeline now looms as a critical junction. While the Risk-to-Remedy platform addresses a genuine regulatory and ethical need, it has not yet demonstrated the concrete revenue generation that would justify the stock’s earlier highs. The coming months will show whether the product’s commercial traction — or the successful close of the Resulticks acquisition — can reverse the 36% slide and pull Diginex out of its oversold hole.

Ad

Diginex Stock: New Analysis - 7 June

Fresh Diginex information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Diginex analysis...

en | KYG286871044 | DIGINEX | boerse | 69496076 |